- Home
- MA vs NVO Comparison
MA vs NVO Comparison
Compare MA & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MA
- NVO
- Stock Information
- Founded
- MA 1966
- NVO 1923
- Country
- MA United States
- NVO Denmark
- Employees
- MA N/A
- NVO N/A
- Industry
- MA Business Services
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MA Consumer Discretionary
- NVO Health Care
- Exchange
- MA Nasdaq
- NVO Nasdaq
- Market Cap
- MA 515.5B
- NVO 530.0B
- IPO Year
- MA 2006
- NVO N/A
- Fundamental
- Price
- MA $559.00
- NVO $82.49
- Analyst Decision
- MA Buy
- NVO Strong Buy
- Analyst Count
- MA 25
- NVO 5
- Target Price
- MA $605.96
- NVO $137.50
- AVG Volume (30 Days)
- MA 2.9M
- NVO 9.5M
- Earning Date
- MA 01-30-2025
- NVO 02-05-2025
- Dividend Yield
- MA 0.54%
- NVO 1.75%
- EPS Growth
- MA 17.41
- NVO 26.84
- EPS
- MA 13.89
- NVO 3.17
- Revenue
- MA $28,167,000,000.00
- NVO $40,469,178,712.00
- Revenue This Year
- MA $15.06
- NVO $24.45
- Revenue Next Year
- MA $12.10
- NVO $21.41
- P/E Ratio
- MA $40.25
- NVO $25.95
- Revenue Growth
- MA 12.23
- NVO 26.15
- 52 Week Low
- MA $428.86
- NVO $78.17
- 52 Week High
- MA $576.94
- NVO $148.15
- Technical
- Relative Strength Index (RSI)
- MA 65.21
- NVO 40.38
- Support Level
- MA $551.07
- NVO $83.90
- Resistance Level
- MA $576.94
- NVO $86.47
- Average True Range (ATR)
- MA 9.42
- NVO 1.99
- MACD
- MA 3.83
- NVO 0.77
- Stochastic Oscillator
- MA 71.62
- NVO 36.57
About MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to over $9 trillion in volume during 2023. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.